Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1681/ASN.2015030337 http://scihub22266oqcxt.onion/10.1681/ASN.2015030337 C4769208!4769208 !26185201     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26185201 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Am+Soc+Nephrol 2016 ; 27 (3 ): 952-62 Nephropedia Template TP {{tp|p=26185201 |t=2016. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up |pdf=|usr=}}{{26185201 }} gab.com Text Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up JO: J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=26185201 #FOAvip Because of the shortage of agalsidase-? supply between 2009 and 2012, patients with Fabry disease either were treated with reduced doses or were switched to agalsidase-?. In this observational study, we assessed end organ damage and clinical symptoms with special focus on renal outcome after 2 years of dose-reduction and/or switch to agalsidase-?. A total of 89 adult patients with Fabry disease who had received agalsidase-? (1.0 mg/kg body wt) for >1 year were nonrandomly assigned to continue this treatment regimen (regular-dose group, n=24), to receive a reduced dose of 0.3-0.5 mg/kg and a subsequent switch to 0.2 mg/kg agalsidase-? (dose-reduction-switch group, n=28), or to directly switch to 0.2 mg/kg agalsidase-? (switch group, n=37) and were followed-up for 2 years. We assessed clinical events (death, myocardial infarction, severe arrhythmia, stroke, progression to ESRD), changes in cardiac and renal function, Fabry-related symptoms (pain, hypohidrosis, diarrhea), and disease severity scores. Determination of renal function by creatinine and cystatin C-based eGFR revealed decreasing eGFRs in the dose-reduction-switch group and the switch group. The Mainz Severity Score Index increased significantly in these two groups (P=0.02 and P<0.001, respectively), and higher frequencies of gastrointestinal pain occurred during follow-up. In conclusion, after 2 years of observation, all groups showed a stable clinical disease course with respect to serious clinical events. However, patients under agalsidase-? dose-reduction and switch or a direct switch to agalsidase-? showed a decline of renal function independent of the eGFR formula used. Twit Text FOAVip Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up ????J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=26185201 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26185201 #FOAvip English Wikipedia <ref>{{Cite pmid|26185201 }}</ref> Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up #MMPMID26185201 Lenders M ; Canaan-Kühl S ; Krämer J ; Duning T ; Reiermann S ; Sommer C ; Stypmann J ; Blaschke D ; Üçeyler N ; Hense HW ; Brand SM ; Wanner C ; Weidemann F ; Brand E J Am Soc Nephrol 2016[Mar]; 27 (3 ): 952-62 PMID26185201 show ga Because of the shortage of agalsidase-? supply between 2009 and 2012, patients with Fabry disease either were treated with reduced doses or were switched to agalsidase-?. In this observational study, we assessed end organ damage and clinical symptoms with special focus on renal outcome after 2 years of dose-reduction and/or switch to agalsidase-?. A total of 89 adult patients with Fabry disease who had received agalsidase-? (1.0 mg/kg body wt) for >1 year were nonrandomly assigned to continue this treatment regimen (regular-dose group, n=24), to receive a reduced dose of 0.3-0.5 mg/kg and a subsequent switch to 0.2 mg/kg agalsidase-? (dose-reduction-switch group, n=28), or to directly switch to 0.2 mg/kg agalsidase-? (switch group, n=37) and were followed-up for 2 years. We assessed clinical events (death, myocardial infarction, severe arrhythmia, stroke, progression to ESRD), changes in cardiac and renal function, Fabry-related symptoms (pain, hypohidrosis, diarrhea), and disease severity scores. Determination of renal function by creatinine and cystatin C-based eGFR revealed decreasing eGFRs in the dose-reduction-switch group and the switch group. The Mainz Severity Score Index increased significantly in these two groups (P=0.02 and P<0.001, respectively), and higher frequencies of gastrointestinal pain occurred during follow-up. In conclusion, after 2 years of observation, all groups showed a stable clinical disease course with respect to serious clinical events. However, patients under agalsidase-? dose-reduction and switch or a direct switch to agalsidase-? showed a decline of renal function independent of the eGFR formula used. |Abdominal Pain/chemically induced [MESH] |Adult [MESH] |Creatinine/blood [MESH] |Cystatin C/blood [MESH] |Drug Substitution/adverse effects [MESH] |Enzyme Replacement Therapy/adverse effects [MESH] |Fabry Disease/complications/*drug therapy/*physiopathology [MESH] |Female [MESH] |Follow-Up Studies [MESH] |Glomerular Filtration Rate/*drug effects [MESH] |Humans [MESH] |Isoenzymes/*administration & dosage/adverse effects/therapeutic use [MESH] |Male [MESH] |Middle Aged [MESH] |Renal Insufficiency, Chronic/etiology/*physiopathology [MESH] |Retrospective Studies [MESH] |Serum Albumin/metabolism [MESH] |Severity of Illness Index [MESH]Patients with Fabry Disease after Enzyme Replacement Therapy Dose Redu(epmc).pdf DeepDyve Pubget Overpricing